insights_auto
Why is CNSY up 9.48%?
Dive Deeperchevron_right
CNSY:NASDAQ
Cerenome, Inc.
$1.79
arrow_upward
+9.48%(+0.15) 1D
$1.78
arrow_downward
-0.34% (-0.0060)bedtimeAfter hours
Closed: Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CNSY...
Open
$1.68
High
$1.80
Low
$1.60
Mkt. cap
13.59M
Avg. vol.
141.55K
Volume
122.72K
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
Open
$1.68
High
$1.80
Low
$1.60
Mkt. cap
13.59M
Avg. vol.
141.55K
Volume
122.72K
52-wk high
$4.16
52-wk low
$1.48
EPS
-$4.42
Beta
1.47
Shares outstanding
7.59M
No. of employees
28
News stories
From web sources and news partners
CNBC
·
30 minutes ago
Jim Cramer talks what lead the Dow higher while the Nasdaq sunk
TradingView
·
2 hours ago
Analyst Sets Stark S&P 500 Target For 2027
ChartMill
·
4 hours ago
Top S&P500 movers in Thursday's session
AOL.com
·
49 minutes ago
History Says Every S&P 500 Bull Market That Reached Its 4th Birthday Kept Going
Profile
Cerenome, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Cerenome also commercialized a molecular diagnostic service, CNSide®. Wikipedia
About Cerenome, Inc.